sur ADOCIA (EPA:ADOC)
Adocia: Financial report for the fourth quarter of 2024
Biopharmaceutical company Adocia, which specializes in treating diabetes and obesity, has released its financial results for the last quarter of 2024. The company's cash position stands at €7.5 million as of December 31, 2024, compared to €13 million at the end of 2023. This decline reflects the year's operational activities and strategic investments.
Adocia reported revenue of €9.3 million for the quarter, driven by a $10 million milestone payment from Tonghua Dongbao related to the BioChaperone® Lispro study. The company is continuing its partnership discussions with Sanofi for M1Pram, and is also focusing on the development of BioChaperone® CagriSema.
The company also highlighted its AdoShell® technology for cell therapy, highlighting significant preclinical advances. Adocia plans to continue its collaboration for the AdOral® technology, focused on the oral delivery of peptides.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ADOCIA